admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Mycrodose Therapeutics Successfully Completes Oversubscribed Private Placement to Expand Existing Patent...

Are Prodrugs the Next Wave of Psychedelic Drug Development?

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a...

Small Pharma Successfully Completes Phase I Clinical Trial of DMT in...

DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine)...

Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved...

PT263 – Michelle Janikian – 920: The Magic Mushroom Holiday

Beckley Psytech announces first patient has received low-dose psilocybin in world-first...

Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA...

Amanita muscaria – A Fresh Look at An Iconic Mushroom

1...195196197...218 Page 196 of 218

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin